The most severe adverse events (grades 3/4) with GEMZAR plus carboplatin for the treatment of patients with advanced ovarian cancer were neutropenia (71%), thrombocytopenia (35%), leukopenia (53%), anemia (28%), nausea (6%), vomiting (6%), and constipation (7%). The most common adverse events (all grades) were RBC transfusion (38%), alopecia (49%), neuropathy/sensory (29%), nausea (69%), fatigue (40%), vomiting (46%), diarrhea (25%), and constipation (42%).
See complete Warnings, Precautions, Adverse Reactions, and Dosage and Administration sections in the accompanying full Prescribing Information for safety and dosing guidelines.
About Lilly Oncology, a Division of Eli Lilly and Company
For more than four decades, Lilly Oncology has been collaborating with cancer researchers to deliver innovative treatment choices and valuable programs to patients and their physicians. Inspired by courageous patients living with cancer, Lilly Oncology is providing treatments that are considered global standards of care and developing a broad portfolio of novel targeted therapies to accelerate the pace and progress of cancer care. To learn more about Lilly's commitment to cancer, please visit www.LillyOncology.com.
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs.
P--LLY
ALIMTA(R) (pemetrexed for injection), Lilly
GEMZAR(R) (gemcitabine HCl for injection), Lilly
bevacizumab (Avastin(R)), Genentech
oxaliplatin (Eloxatin(R)), Sanofi Aventis
erlotinib (Tarceva(R)), Genentech, OSI Pharmaceuticals
cetuximab (Erbitux(R)), Bristol-Myers Squibb, ImClone, Merck
vandetanib (Zactima(TM)), AstraZeneca
This press release contains forward-looking statements about the potential of ALIMTA and GEMZAR for the treatment of non-small cell lung cancer and reflects Lilly's current beliefs. However, as with any pharmaceutical products under development, there are substantial risks and uncertainties in the process of development, commercialization, and regulatory review. There is no guarantee that the products will receive additional regulatory approvals. There is also no guarantee that the products will continue to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filing with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.
(i) Parkin DM, Bray F, Ferlay J, Pisani P, Global Cancer Statistics,
2002. CA Cancer J Clin 2005;55;74-108.
(ii) Gronberg, BH. Pemetrexed+carboplatin vs. gemcitabine+carboplatin in
the treatment of stage IIIB/IV non-small cell lung cancer. Abstract
#7517, American Society of Clinical Oncology (ASCO) Annual Meeting
2007.
(iii) Heist RS, Auerbach M, et al. Phase II trial of oxaliplatin,
pemetrexed, and bevacizumab in previously-treated advanced non-
small cell lung cancer (NSCLC). Abstract #7700, American Society of
Clinical Oncology (ASCO) Annual Meeting 2007.
(iv) Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with
oxaliplatin or carboplatin as first-line treatment in advanced non-
small cell lung cancer: a multicenter, randomized, phase II trial.
Clin Cancer Res. 2005 Jan 15;11 (2 Pt 1):690-6.
(v) Zinner RG, Fossella FV, Gladish GW, et al. Phase II study of
pemetrexed in combination with carboplatin in the first-line
treatment of advanced nonsmall cell lung cancer. Cancer. 2005 Dec
1;104(11):2449-56.
(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )
Gregory L. Clarke of Lilly, +1-317-276-5222, +1-317-554-7119 (mobile), gregory.clarke@lilly.com; or Neil Hochman of CPR Worldwide, +1-212-453-2067, +1-516-784-9089 (mobile), n.hochman@cprworldwideusa.com . Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO , PRN Photo Desk, photodesk@prnewswire.com
